Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

27 Sep 2023

Nanopharm Case Study on Computational Modelling


The pharmaceutical industry is witnessing a significant shift in the reformulation of injectable drug products for nasal delivery. This article presents a case study of using modelling to accelerate the reformulation process. The focus is on Nanopharm’s SmartTrack™, a process that combines breath profiles recording with realistic aerodynamic particle size distribution performance testing, in-vitro dissolution, and morphology directed particle sizing and chemical imaging of a representative lung dose and regional deposition modelling.

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »